Tests whether exercise can lower signs of cancer returning
Tests aerobic exercise in adults treated earlier for breast, prostate or colorectal cancer.
Key facts
- Who runs it
- City of Hope Medical Center
- Where
- Basking Ridge, Commack, Durate, Harrison, Middletown, Montvale, New York, San Carlos, and Uniondale, United StatesSee the 9 sites
- Trial code
- Registry title
- Researching the Effect of Exercise on Cancer
- Status
- Recruiting
- People taking part
- 51 people, planned
- Started
- 12 Oct 2026
- Expected to end
- 13 Feb 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Exercise
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who finished treatment for a high-risk breast, prostate or colorectal cancer (or other high-risk solid tumor), have no sign of disease, and do little exercise now.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- A high-risk solid tumor after surgery, such as colorectal (colorectal only for Phase 1a), ovarian or non-small cell lung cancer. Either stage 3 or ctDNA positive. High-risk breast cancer with leftover invasive disease after chemotherapy given before surgery, ER and/or PR positive and HER2 negative, with certain risk scores. No evidence of disease.
- Earlier treatment
- All main follow-up treatment (adjuvant therapy) must be finished 1 month to 2 years ago. For breast cancer, chemotherapy before surgery (NACT) must have been completed.
- Biomarker or test result
- ctDNA positive (for high-risk solid tumors). For breast cancer: ER and/or PR positive, HER2 negative, and a CPS-EG score of 3 or more, or 2 or more with ypN+, or a recurrence score of 25 or more.
Main reasons for not taking part
- Taking part in another interventional study, unless the study lead decides it does not affect the results
- Any other current invasive cancer
- Distant spread (metastatic) cancer of any kind
- Not cleared for exercise by the PAR-Q+ screening
- Any other illness that the investigator thinks makes joining a poor choice
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Postsurgical diagnosis of patients with primary solid tumors at high-risk of relapse as defined by one of the following:; ° High-risk primary solid tumor (e.g., colorectal, ovarian, non-small cell lung cancer) (colorectal cancer only for Phase 1a)
- Stage 3 or
- ctDNA positive; ° High-risk breast cancer
- Residual invasive disease in the breast or the lymph nodes following completion of neoadjuvant chemotherapy (NACT),
- Estrogen receptor (ER), and/or progesterone receptor (PR) positive and HER2 negative,
- CPS-EG score ≥ 3,
- CPS-EG score ≥2 w ith ypN+, or
- Recurrence score ≥ 25
- No evidence of disease
- Age ≥ 18
- Interval of ≥ 1 month but ≤ 2 years following completion of all definitive adjuvant therapy
- Non-exercising (i.e., < 30 minutes of moderate and < 20 mins of vigorous exercise/wk), as assessed by remote activity and heart rate tracking for a 7-day period prior to study entry); ° If ≥ 30 minutes but less than 45 minutes of moderate exercise/week, or if ≥ 20 minutes but less than 30 minutes of vigorous exercise/week, patients may be eligible, at the discretion of the PI
- Cleared for exercise participation as per screening clearance via PAR-Q+
- Willingness to comply with all study-related procedures
Who cannot take part
- Any other current diagnosis of invasive cancer of any kind
- Distant metastatic malignancy of any kind
- Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation
- Enrollment onto any other interventional investigational study except interventions determined by the PI not to confound study outcomes
Where in United States
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking Ridge, United StatesContact: Lee Jones, MDNo longer taking part
- Memorial Sloan Kettering Commack (Limited protocol activities)Commack, United StatesContact: Lee Jones, MDNo longer taking part
- City of Hope Medical CenterDurate, United StatesContact: Lee Jones, MDTaking people
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)Harrison, United StatesContact: Lee Jones, MDNo longer taking part
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown, United StatesContact: Lee Jones, MDNo longer taking part
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale, United StatesContact: Lee Jones, MDNo longer taking part
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Lee Jones, MDNo longer taking part
- Natera, Inc. (Data or Specimen Analysis Only)San Carlos, United StatesContact: Shifra KrinshpunNot yet recruiting
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)Uniondale, United StatesContact: Lee Jones, MDNo longer taking part
About the trial
What the trial wants to find out
Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that stimulates and strengthens the heart and lungs and improves the body's use of oxygen) can reduce the level of ctDNA found in the blood. During the study, the highest level of exercise that is practical, is safe, and has positive effects on the body that may prevent the return of cancer (including a decrease in ctDNA levels) will be found. Each level of exercise tested will be a certain number of minutes each week. Once the best level of exercise is found, it will be tested further in a new group of participants. All participants in this study will have been previously treated for breast, prostate, or colorectal cancer.
The 2 groups in the trial
- Dose-Finding/EscalationTreatment being tested
Fifty (n=50) post-treatment patients with colorectal cancer or breast cancer, deemed high-risk of relapse. The study will use an adaptive continuous reassessment method (CRM) design to assign patients sequentially at trial entry to one of five escalated doses depending on the feasibility / tolerability of exercise therapy evaluated over the total treatment period. The primary objective of this phase 1a trial is to identify the RP2D of exercise therapy for further evaluation in the phase 1b trial.
Treatment: Exercise
- Dose ExpansionTreatment being tested
An independent cohort of 30 post-treatment patients with colorectal (n=15) or breast (n=15) cancer deemed high-risk of relapse. This cohort expansion trial will only evaluate the RP2D identified in the phase 1a trial. The primary objective of this phase 1b trial is to further evaluate the feasibility, safety, and biological activity of the RP2D.
Treatment: Exercise
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Phase 1a/b Trial of Exercise as Interception Therapy for Primary High-Risk Cancer
- Plain-language title
- Tests whether exercise can lower signs of cancer returningGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 November 2026